Forest Laboratories (FRA:FQX) Debt-to-Equity : 0.49 (As of Mar. 2014)

View and export this data going back to . Start your Free Trial

What is Forest Laboratories Debt-to-Equity?

Forest Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2014 was €0 Mil. Forest Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2014 was €2,169 Mil. Forest Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2014 was €4,458 Mil. Forest Laboratories's debt to equity for the quarter that ended in Mar. 2014 was 0.49.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Forest Laboratories's Debt-to-Equity or its related term are showing as below:

FRA:FQX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0 Max: 0
Current: 0.49

FRA:FQX's Debt-to-Equity is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.3 vs FRA:FQX: 0.49

Forest Laboratories Debt-to-Equity Historical Data

The historical data trend for Forest Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forest Laboratories Debt-to-Equity Chart

Forest Laboratories Annual Data

Trend

Mar05

Mar06

Mar07

Mar08

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Debt-to-Equity

Get a 7-Day Free Trial

0.49

Forest Laboratories Quarterly Data
	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14
Debt-to-Equity	Get a 7-Day Free Trial															-	-	-	0.20	0.49

Competitive Comparison of Forest Laboratories's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forest Laboratories's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Forest Laboratories's Debt-to-Equity falls into.

Forest Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Forest Laboratories's Debt to Equity Ratio for the fiscal year that ended in Mar. 2014 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	2169)	/	4457.703
	=	0.49

Forest Laboratories's Debt to Equity Ratio for the quarter that ended in Mar. 2014 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0	+	2169)	/	4457.703
	=	0.49

Forest Laboratories (FRA:FQX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Forest Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Forest Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Forest Laboratories (FRA:FQX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Forest Laboratories Inc (FRA:FQX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.frx.com

Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Forest Laboratories (FRA:FQX) Headlines

No Headlines